Humana to Host Biennial Investor Meeting


Tuesday, December 2, 2014 4:15 pm EST



Public Company Information:


LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced that it will be hosting an Investor Meeting in New York City on Thursday, December 4, 2014, at 9:00 a.m. eastern time. The Investor Meeting will include a number of presentations by company leaders focusing on Humana’s strategic direction, operational and financial progress and expectations for future performance.

At the Investor Meeting, the company will reiterate its guidance for the years ending December 31, 2014 and 2015 as filed with the Securities and Exchange Commission on November 7, 2014 in conjunction with its third quarter 2014 earnings release. A copy of those detailed guidance points is included with this release.

Humana encourages the investing public and media to listen to its Investor Meeting via the Internet since attendance at the event is by invitation only. The Investor Meeting webcast and virtual presentation (audio with slides) may be accessed via Humana’s Investor Relations page at The company suggests web participants sign on approximately 15 minutes in advance of the event. The company also suggests web participants visit the site in advance to run a system test and to download any free software needed.

Below is the agenda for the event:

  Humana’s Investor Meeting 2014  

Thursday, December 4, 2014; 9:00 a.m. ET
Webcast available via Investor Relations page at

Topic         Speaker        
Welcome Regina Nethery Vice President, Investor Relations
Strategic Overview Bruce Broussard President and Chief Executive Officer
The Consumer Experience Jody Bilney Senior Vice President and Chief Consumer Officer
Integrated Care Delivery Jim Murray Executive Vice President and Chief Operating Officer
The Power of Data Analytics Marsden Connolly Segment Vice President and President, Clinical Care Services
Brian LeClaire, PhD Senior Vice President and Chief Information Officer
Humana At Home Marsden Connolly Segment Vice President and President, Clinical Care Services
Eric Rackow, MD President, Humana At Home
Population Health/Continuum of Care Roy Beveridge, MD Senior Vice President and Chief Medical Officer
Tim O’Rourke Segment Vice President, Provider Development
Jaewon Ryu, MD Segment Vice President and President, Integrated Care Delivery
Humana Pharmacy William Fleming, PharmD Segment Vice President and President, Humana Pharmacy
Integrated Care Delivery Q&A
Retail Segment Strategy Jim Murray Executive Vice President and Chief Operating Officer
Retail Segment Operations Alan Wheatley President, Retail Segment
Retail Segment Q&A
Financial Update Brian Kane Senior Vice President and Chief Financial Officer
  Final Wrap-up / Q&A                      

Cautionary Statement

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:

  • If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of health care services delivered to its members, if the company is unable to implement clinical initiatives to provide a better health care experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate , Humana’s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. These estimates, however, involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends.
  • If Humana fails to effectively implement its operational and strategic initiatives, particularly its Medicare initiatives, state-based contract strategy, and its participation in the new health insurance exchanges, the company’s business may be materially adversely affected, which is of particular importance given the concentration of the company’s revenues in these products.
  • If Humana fails to properly maintain the integrity of its data, to strategically implement new information systems, to protect Humana’s proprietary rights to its systems, or to defend against cyber-security attacks, the company’s business may be materially adversely affected.
  • Humana’s business may be materially adversely impacted by CMS’s adoption of a new coding set for diagnoses (commonly known as ICD-10), the implementation of which has been deferred to at least October 1, 2015.
  • Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes relating to rate adjustments resulting from the Balanced Budget and Emergency Deficit Control Act of 1985, as amended, commonly referred to as “sequestration”; other provider contract disputes; and qui tam litigation brought by individuals on behalf of the government) and governmental and internal investigations, any of which, if resolved unfavorably to the company, could result in substantial monetary damages. Increased litigation and negative publicity could also increase the company’s cost of doing business.
  • As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government health care programs including, among other things, loss of material government contracts, governmental audits and investigations, potential inadequacy of government-determined payment rates, potential restrictions on profitability, including by comparison of profitability of the company’s Medicare Advantage business to non-Medicare Advantage business, or other changes in the governmental programs in which Humana participates.
  • The Health Care Reform Law, including The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010, could have a material adverse effect on Humana’s results of operations, including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company’s ability to expand into new markets, increasing the company’s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company’s Medicare payment rates and increasing the company’s expenses associated with a non-deductible health insurance industry fee and other assessments; the company’s financial position, including the company’s ability to maintain the value of its goodwill; and the company’s cash flows. In addition, if Humana is unable to adjust its business model to address the non-deductible health insurance industry fee and other assessments, including the three-year commercial reinsurance fee, such as through the reduction of the company’s operating costs, there can be no assurance that the non-deductible health insurance industry fee and other assessments would not have a material adverse effect on the company’s results of operations, financial position, and cash flows.
  • Humana’s participation in, and the operational functionality of, the new federal and state health care exchanges, which have experienced certain technical difficulties in their early implementation and which entail uncertainties associated with mix and volume of business, could adversely affect the company’s results of operations, financial position, and cash flows.
  • Humana’s business activities are subject to substantial government regulation. New laws or regulations, or changes in existing laws or regulations or their manner of application could increase the company’s cost of doing business and may adversely affect the company’s business, profitability and cash flows.
  • Any failure to manage operating costs could hamper Humana’s profitability.
  • Any failure by Humana to manage acquisitions and other significant transactions successfully may have a material adverse effect on its results of operations, financial position, and cash flows.
  • If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company’s business may be adversely affected.
  • Humana’s pharmacy business is highly competitive and subjects it to regulations in addition to those the company faces with its core health benefits businesses.
  • Changes in the prescription drug industry pricing benchmarks may adversely affect Humana’s financial performance.
  • If Humana does not continue to earn and retain purchase discounts and volume rebates from pharmaceutical manufacturers at current levels, Humana’s gross margins may decline.
  • Humana’s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.
  • Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.
  • Changes in economic conditions could adversely affect Humana’s business and results of operations.
  • The securities and credit markets may experience volatility and disruption, which may adversely affect Humana’s business.
  • Given the current economic climate, Humana’s stock and the stock of other companies in the insurance industry may be increasingly subject to stock price and trading volume volatility.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

  • Form 10-K for the year ended December 31, 2013;
  • Form 10-Q for the quarter ended March 31, 2014, June 30, 2014, and September 30, 2014;
  • Form 8-Ks filed during 2014.

About Humana

Humana Inc., headquartered in Louisville, Ky., is a leading health and well-being company focused on making it easy for people to achieve their best health with clinical excellence through coordinated care. The company’s strategy integrates care delivery, the member experience, and clinical and consumer insights to encourage engagement, behavior change, proactive clinical outreach and wellness for the millions of people we serve across the country.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at, including copies of:

  • Annual reports to stockholders
  • Securities and Exchange Commission filings
  • Most recent investor conference presentations
  • Quarterly earnings news releases
  • Replays of most recent earnings release conference calls
  • Calendar of events (including upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
  • Corporate Governance information

Humana Inc. – Earnings Guidance Points as Issued on November 7, 2014


(in accordance with Generally Accepted
Accounting Principles)


For the year ending
December 31, 2014 (FY14)


For the year ending
December 31, 2015 (FY15)

  Diluted earnings per common share    

$7.40 to $7.60 (adjusted)(a)

    $8.50 to $9.00     (a) Adjusted earnings per share for 2014 excludes
approximately $0.15 per share associated with
the early retirement of debt in the fourth quarter
of 2014. The Company has included this financial
measure (not in accordance with Generally
Accepted Accounting Principles (GAAP)) in its
summary of financial results within this earnings
press release as management believes that this
measure, when presented in conjunction with
the comparable GAAP measure, is useful to both
management and its investors in analyzing the
company’s ongoing business and operating
performance. The excluded item (retirement of
debt) is not a recurring part of the company’s
operating plan. Consequently, management uses
this non-GAAP financial measure as an indicator
of business performance, as well as for
operational planning and decision making
purposes. Non-GAAP financial measures should
be considered in addition to, but not as a
substitute for, or superior to, financial measures
prepared in accordance with GAAP. To reconcile
the non-GAAP to the GAAP amount,
approximately $0.15 per share associated with
the early retirement of debt in the fourth quarter
of 2014 should be deducted, to arrive at GAAP

EPS guidance of $7.25 to $7.45.

Revenues Revenues include expected interest
Consolidated $48 billion to $49 billion $53.5 billion to $54.5 billion income.
Segments Segment-level revenues include
Retail Segment $33.5 billion to $34.5 billion $38.5 billion to $40.0 billion intersegment amounts that
eliminate in consolidation.
Employer Group Segment $12.0 billion to $12.5 billion $12 billion to $13 billion

Healthcare Services Segment

    $19.5 billion to $20.0 billion     $22.5 billion to $23.5 billion        
Consolidated investment income $350 million to $400 million $350 million to $400 million Investment income is included in
                    revenue guidance above.  
Ending medical membership; and changes
Retail Segment
Medicare Advantage (MA)

2,443,700 to 2,453,700; Up 375,000 to

2,683,700 to 2,703,700; Up Includes MA membership sold


235,000 to 255,000 directly to individuals as well as
dual-eligible MA members from
state-based contracts.



Medicare stand-alone PDPs

3,829,100 to 3,879,100; Up 650,000

4,329,100 to 4,379,100; Up Medicare stand-alone PDPs

to 700,000

475,000 to 525,000 exclude Limited Income Newly
Eligible Transitions (LI-NET)




State-based Medicaid

275,500 to 295,500; Up 190,000 to

285,500 to 290,500; Flat to Up Includes Medicaid Temporary



Assistance for Needy Families
(TANF) which contracts are
generally reinsured through
partnering relationships, and
Long-Term Support Services
(LTSS) membership from state-
based contracts.
Individual commercial 980,400 to 1,030,400; Up 475,000 to 915,400 to 925,400; Down Includes membership expectations


80,000 to 90,000 for both on-exchange and off-
exchange enrollment.
Medicare Supplement 129,700 to 139,700; Up 35,000 to 170,000 to 180,000; Up


35,000 to 45,000
Employer Group Segment
Medicare Advantage 479,100 to 499,100; Up 50,000 to 479,100 to 489,100; Flat to


Down 10,000
Commercial fully-insured 1,187,000 to 1,197,000; Down 40,000 1,162,000 to 1,172,000; Down
to 50,000 20,000 to 30,000
Commercial ASO 1,092,800 to 1,102,800; Down 60,000 672,800 to 697,800; Down
        to 70,000     400,000 to 425,000        
Benefit ratios Benefits expense as a percent of
Retail Segment 83.5% to 84.5% 83.5% to 84.5%


  Employer Group Segment     83.5% to 84.5%     83.5% to 84.5%        
Operating cost ratios Operating costs as a percent of
Consolidated 15.75% to 16.25% 14.5% to 15.5% total revenues excluding
investment income.
  Healthcare Services Segment     95.25% to 95.75%     95.5% to 96.0%        
Consolidated depreciation and amortization Certain D&A is included in benefits
(D&A) expense on the income statement
Income statement $330 million to $340 million $350 million to $370 million but shown as a non-cash item on
the cash flows statement.
  Cash flows statement     $435 million to $445 million     $470 million to $490 million        
Consolidated interest expense $190 million to $195 million $185 million to $190 million Interest expense for FY14 includes
$0.15 per share of expenses
from early retirement of debt in
Pretax results Segment-level pretax results
include the impact of net
investment income.
Retail Segment $1.13 billion to $1.18 billion $1.425 billion to $1.525 billion FY15 includes $0.30 to $0.35 per
share of investment spending
related to state-based contracts.
Employer Group Segment $250 million to $290 million $275 million to $325 million
  Healthcare Services Segment     $725 million to $775 million     $775 million to $825 million        
Effective Tax Rate 46% to 47% 49.0% to 49.5% Reflects the non-deductibility of the
                    industry fee.  
Weighted average shares for diluted earnings per Approximately 156 million Approximately 150 million Reflects impact of repurchases.
  common share                    
Cash flows from operations $1.1 billion to $1.4 billion $1.5 billion to $1.8 billion Includes anticipated FY14
receivables of $700 million to
$750 million and FY15
receivables of $325 million to
$400 million related to health
care exchange risk adjustment,
reinsurance, and risk corridor
  Capital expenditures         $500 million to $525 million         $575 million to $625 million            


Humana Inc.
Regina Nethery, 502-580-3644
Investor Relations
Tom Noland, 502-580-3674
Corporate Communications